Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
- PMID: 33526596
- PMCID: PMC7896311
- DOI: 10.1073/pnas.2021946118
Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
Abstract
The RNA polymerase inhibitor favipiravir is currently in clinical trials as a treatment for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), despite limited information about the molecular basis for its activity. Here we report the structure of favipiravir ribonucleoside triphosphate (favipiravir-RTP) in complex with the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) bound to a template:primer RNA duplex, determined by electron cryomicroscopy (cryoEM) to a resolution of 2.5 Å. The structure shows clear evidence for the inhibitor at the catalytic site of the enzyme, and resolves the conformation of key side chains and ions surrounding the binding pocket. Polymerase activity assays indicate that the inhibitor is weakly incorporated into the RNA primer strand, and suppresses RNA replication in the presence of natural nucleotides. The structure reveals an unusual, nonproductive binding mode of favipiravir-RTP at the catalytic site of SARS-CoV-2 RdRp, which explains its low rate of incorporation into the RNA primer strand. Together, these findings inform current and future efforts to develop polymerase inhibitors for SARS coronaviruses.
Keywords: COVID-19; T-705; cryoEM; drug design; structural biology.
Copyright © 2021 the Author(s). Published by PNAS.
Conflict of interest statement
The authors declare no competing interest.
Figures




Similar articles
-
Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin.Nat Struct Mol Biol. 2021 Mar;28(3):319-325. doi: 10.1038/s41594-021-00570-0. Epub 2021 Mar 5. Nat Struct Mol Biol. 2021. PMID: 33674802
-
Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).Molecules. 2022 Jan 26;27(3):801. doi: 10.3390/molecules27030801. Molecules. 2022. PMID: 35164069 Free PMC article.
-
Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.Int J Mol Sci. 2022 Sep 20;23(19):11009. doi: 10.3390/ijms231911009. Int J Mol Sci. 2022. PMID: 36232311 Free PMC article.
-
Favipiravir and COVID-19: A Simplified Summary.Drug Res (Stuttg). 2021 Mar;71(3):166-170. doi: 10.1055/a-1296-7935. Epub 2020 Nov 11. Drug Res (Stuttg). 2021. PMID: 33176367 Free PMC article. Review.
-
The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2.Biochem Biophys Res Commun. 2021 Jan 29;538:63-71. doi: 10.1016/j.bbrc.2020.10.091. Epub 2020 Nov 21. Biochem Biophys Res Commun. 2021. PMID: 33288200 Free PMC article. Review.
Cited by
-
On the Recognition of Natural Substrate CTP and Endogenous Inhibitor ddhCTP of SARS-CoV-2 RNA-Dependent RNA Polymerase: A Molecular Dynamics Study.J Chem Inf Model. 2022 Oct 24;62(20):4916-4927. doi: 10.1021/acs.jcim.2c01002. Epub 2022 Oct 11. J Chem Inf Model. 2022. PMID: 36219674 Free PMC article.
-
Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance.Microorganisms. 2021 May 19;9(5):1094. doi: 10.3390/microorganisms9051094. Microorganisms. 2021. PMID: 34069681 Free PMC article.
-
Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.Front Pharmacol. 2022 Feb 25;13:840639. doi: 10.3389/fphar.2022.840639. eCollection 2022. Front Pharmacol. 2022. PMID: 35281901 Free PMC article. Review.
-
Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.J Pers Med. 2022 Jun 18;12(6):995. doi: 10.3390/jpm12060995. J Pers Med. 2022. PMID: 35743779 Free PMC article. Review.
-
Repurposing of anti-lung cancer drugs as multi-target inhibitors of SARS-CoV-2 proteins: An insight from molecular docking and MD-simulation study.Microb Pathog. 2022 Aug;169:105615. doi: 10.1016/j.micpath.2022.105615. Epub 2022 Jun 8. Microb Pathog. 2022. PMID: 35690231 Free PMC article.
References
-
- Chen C., et al. , Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv [Preprint] (2020). 10.1101/2020.03.17.20037432 (Accessed 1 September 2020). - DOI
-
- Rattanaumpawan P., Jirajariyavej S., Lerdlamyong K., Palavutitotai N., Saiyarin J., Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multicenter observational study. medRxiv [Preprint] (2020). 10.1101/2020.06.24.20133249 (Accessed 1 September 2020). - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous